JP Morgan Chase’s AbbVie ABBV Stock Holding History

JP Morgan Chase’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.2B	Sell	47,862,796 -8,878,895	-16%	-$1.91B	0.67%	20
2026 Q1	$12.1B	Buy	56,741,691 +4,348,368	+8%	+$965M	0.78%	19
2025 Q4	$12B	Sell	52,393,323 -4,141,493	-7%	-$943M	0.75%	18
2025 Q3	$13.1B	Sell	56,534,816 -679,591	-1%	-$138M	0.78%	15
2025 Q2	$10.6B	Buy	57,214,407 +2,459,937	+4%	+$457M	0.69%	16
2025 Q1	$11.5B	Buy	54,754,470 +2,991,979	+6%	+$582M	0.84%	14
2024 Q4	$9.2B	Sell	51,762,491 -549,610	-1%	-$101M	0.68%	21
2024 Q3	$10.3B	Sell	52,312,101 -1,245,814	-2%	-$233M	0.79%	17
2024 Q2	$9.19B	Buy	53,557,915 +2,112,885	+4%	+$350M	0.75%	17
2024 Q1	$9.37B	Sell	51,445,030 -577,916	-1%	-$99.6M	0.79%	13
2023 Q4	$8.06B	Sell	52,022,946 -3,207,862	-6%	-$468M	0.77%	13
2023 Q3	$8.23B	Sell	55,230,808 -1,541,772	-3%	-$226M	0.91%	12
2023 Q2	$7.65B	Sell	56,772,580 -1,125,984	-2%	-$165M	0.83%	13
2023 Q1	$9.23B	Sell	57,898,564 -3,011,650	-5%	-$460M	1.12%	7
2022 Q4	$9.84B	Buy	60,910,214 +2,431,205	+4%	+$373M	1.3%	5
2022 Q3	$7.85B	Buy	58,479,009 +2,368,374	+4%	+$340M	1.13%	7
2022 Q2	$8.59B	Buy	56,110,635 +2,016,437	+4%	+$308M	1.2%	8
2022 Q1	$8.77B	Buy	54,094,198 +10,989,210	+25%	+$1.6B	1.06%	9
2021 Q4	$5.84B	Sell	43,104,988 -788,370	-2%	-$93.1M	0.67%	17
2021 Q3	$4.73B	Buy	43,893,358 +8,932,364	+26%	+$1.02B	0.59%	20
2021 Q2	$3.94B	Buy	34,960,994 +1,296,199	+4%	+$146M	0.47%	32
2021 Q1	$3.64B	Buy	33,664,795 +3,319,300	+11%	+$355M	0.49%	29
2020 Q4	$3.25B	Buy	30,345,495 +1,154,922	+4%	+$111M	0.48%	38
2020 Q3	$2.54B	Buy	29,190,573 +539,914	+2%	+$50.8M	0.43%	44
2020 Q2	$2.81B	Buy	28,650,659 +6,209,868	+28%	+$547M	0.54%	30
2020 Q1	$1.71B	Buy	22,440,791 +4,486,784	+25%	+$382M	0.4%	52
2019 Q4	$1.59B	Buy	17,954,007 +4,527,315	+34%	+$376M	0.3%	71
2019 Q3	$1.02B	Buy	13,426,692 +9,175,219	+216%	+$629M	0.2%	111
2019 Q2	$298M	Buy	4,251,473 +354,165	+9%	+$27.8M	0.06%	331
2019 Q1	$314M	Sell	3,897,308 -1,702,583	-30%	-$139M	0.06%	307
2018 Q4	$516M	Sell	5,599,891 -1,530,738	-21%	-$135M	0.12%	184
2018 Q3	$674M	Sell	7,130,629 -419,218	-6%	-$39.8M	0.13%	166
2018 Q2	$699M	Buy	7,549,847 +220,185	+3%	+$21.5M	0.14%	149
2018 Q1	$694M	Buy	7,329,662 +1,342,571	+22%	+$147M	0.15%	152
2017 Q4	$579M	Buy	5,987,091 +2,512,893	+72%	+$237M	0.12%	181
2017 Q3	$309M	Buy	3,474,198 +109,529	+3%	+$8.34M	0.07%	297
2017 Q2	$244M	Buy	3,364,669 +678,112	+25%	+$45.6M	0.06%	346
2017 Q1	$175M	Sell	2,686,557 -695,965	-21%	-$43.8M	0.04%	444
2016 Q4	$212M	Sell	3,382,522 -3,876,836	-53%	-$237M	0.05%	377
2016 Q3	$458M	Buy	7,259,358 +1,279,816	+21%	+$82.9M	0.11%	204
2016 Q2	$370M	Sell	5,979,542 -428,469	-7%	-$26.1M	0.09%	245
2016 Q1	$366M	Buy	6,408,011 +143,902	+2%	+$8.02M	0.09%	244
2015 Q4	$371M	Sell	6,264,109 -1,608,155	-20%	-$92.6M	0.09%	243
2015 Q3	$428M	Sell	7,872,264 -1,170,667	-13%	-$76.2M	0.11%	200
2015 Q2	$608M	Sell	9,042,931 -795,301	-8%	-$51.9M	0.14%	168
2015 Q1	$576M	Buy	9,838,232 +606,037	+7%	+$36.6M	0.13%	178
2014 Q4	$604M	Buy	9,232,195 +444,243	+5%	+$28M	0.14%	171
2014 Q3	$508M	Buy	8,787,952 +2,027,023	+30%	+$113M	0.12%	189
2014 Q2	$382M	Buy	6,760,929 +177,216	+3%	+$9.3M	0.1%	238
2014 Q1	$338M	Sell	6,583,713 -532,194	-7%	-$26.9M	0.09%	241
2013 Q4	$376M	Sell	7,115,907 -3,001,977	-30%	-$148M	0.11%	222
2013 Q3	$453M	Buy	10,117,884 +584,537	+6%	+$25.9M	0.13%	176
2013 Q2	$394M	Buy	+9,533,347	New	+$417M	0.13%	192

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JP Morgan Chase's ABBV Position: Q2 2026 in Review

JP Morgan Chase reduced its AbbVie (ABBV) stake by 16% in Q2 2026, selling an estimated $1.91B and leaving 47,862,796 shares worth $12.2B. The position accounts for 0.67% of the portfolio, ranked #20.

JP Morgan Chase first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.1B in Q3 2025. 4,058 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

JP Morgan Chase held 47,862,796 shares of AbbVie worth $12.2B as of Q2 2026.
JP Morgan Chase sold 8,878,895 AbbVie shares in Q2 2026, an estimated $1.91B.
AbbVie made up 0.67% of JP Morgan Chase's portfolio in Q2 2026, its #20 holding.
JP Morgan Chase first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
JP Morgan Chase's AbbVie position peaked at $13.1B in Q3 2025.
4,058 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.